Advertisement

Emerging Treatment Options for Fibroids

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bulun S.E.
        Uterine fibroids.
        N Engl J Med. 2013; 369: 1344-1355
        • Munro M.G.
        • Critchley H.O.D.
        • Broder M.S.
        • et al.
        FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.
        Int J Gynecol Obstet. 2011; 113: 3-13
        • Laughlin-Tommaso S.K.
        • Hesley G.K.
        • Hopkins M.R.
        • et al.
        Clinical limitations of the International Federation of Gynecology and Obstetrics (FIGO) classification of uterine fibroids.
        Int J Gynecol Obstet. 2017; 139: 143-148
        • Ghant M.S.
        • Sengoba K.S.
        • Recht H.
        • et al.
        Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women's emotional and psychosocial health.
        J Psychosom Res. 2015; 78: 499-503
        • Cardozo E.R.
        • Clark A.D.
        • Banks N.K.
        • et al.
        The estimated annual cost of uterine leiomyomata in the United States.
        Am J Obstet Gynecol. 2012; 206: 211.e1-9
        • Giuliani E.
        • As-Sanie S.
        • Marsh E.E.
        Epidemiology and management of uterine fibroids.
        Int J Gynaecol Obstet. 2020; 149: 3-9
        • Laughlin-Tommaso S.K.
        • Stewart E.A.
        Moving Toward Individualized Medicine for Uterine Leiomyomas.
        Obstet Gynecol. 2018; 132: 961-971
        • Toro J.R.
        • Travis L.B.
        • Wu H.J.
        • et al.
        Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases.
        Int J Cancer. 2006; 119: 2922-2930
      1. Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822.
        Obstet Gynecol. 2021; 137: e63-e74
        • Laughlin-Tommaso S.K.
        Non-surgical Management of Myomas.
        J Minim Invasive Gynecol. 2018; 25: 229-236
      2. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228.
        Obstet Gynecol. 2021; 137: e100-e115
        • Bofill Rodriguez M.
        • Lethaby A.
        • Farquhar C.
        Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2019; 9: Cd000400
        • Bryant-Smith A.C.
        • Lethaby A.
        • Farquhar C.
        • et al.
        Antifibrinolytics for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2018; 4: Cd000249
        • Sinai Talaulikar V.
        Medical therapy for fibroids: An overview.
        Best Pract Res Clin Obstet Gynaecol. 2018; 46: 48-56
        • Lethaby A.
        • Wise M.R.
        • Weterings M.A.
        • et al.
        Combined hormonal contraceptives for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2019; 2: Cd000154
        • Curtis K.M.
        • Tepper N.K.
        • Jatlaoui T.C.
        • et al.
        U.S. medical eligibility criteria for contraceptive use, 2016.
        MMWR Recomm Rep. 2016; 65: 1-103
        • Matteson K.A.
        • Rahn D.D.
        • Wheeler 2nd, T.L.
        • et al.
        Nonsurgical management of heavy menstrual bleeding: a systematic review.
        Obstet Gynecol. 2013; 121: 632-643
        • Donnez J.
        • Dolmans M.M.
        Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist.
        Fertil Steril. 2020; 114: 739-741
        • Carr B.R.
        • Stewart E.A.
        • Archer D.F.
        • et al.
        Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial.
        Obstet Gynecol. 2018; 132: 1252-1264
        • Al-Hendy A.
        • Lukes A.S.
        • Poindexter 3rd, A.N.
        • et al.
        Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
        N Engl J Med. 2021; 384: 630-642
        • Singh S.S.
        • Belland L.
        • Leyland N.
        • et al.
        The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
        Am J Obstet Gynecol. 2018; 218: 563-572.e1
        • Murji A.
        • Whitaker L.
        • Chow T.L.
        • et al.
        Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
        Cochrane Database Syst Rev. 2017; 2017: CD010770
        • Hartmann K.E.
        • Fonnesbeck C.
        • Surawicz T.
        • et al.
        AHRQ Comparative Effectiveness Reviews.
        in: Management of uterine fibroids. Agency for Healthcare Research and Quality (US), Rockville (MD)2017
        • Donnez J.
        • Dolmans M.M.
        Uterine fibroid management: from the present to the future.
        Hum Reprod Update. 2016; 22: 665-686
      3. SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150, October 2004.
        Int J Gynaecol Obstet. 2005; 89: 305-318
        • Silberzweig J.E.
        • Powell D.K.
        • Matsumoto A.H.
        • et al.
        Management of Uterine Fibroids: A Focus on Uterine-sparing Interventional Techniques.
        Radiology. 2016; 280: 675-692
        • Gupta J.K.
        • Sinha A.
        • Lumsden M.A.
        • et al.
        Uterine artery embolization for symptomatic uterine fibroids.
        Cochrane Database Syst Rev. 2014; 12: Cd005073
        • De Bruijn A.M.
        • Ankum W.M.
        • Reekers J.A.
        • et al.
        Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial.
        Am J Obstet Gynecol. 2016; 215: 745.e1-2
        • Anneveldt K.J.
        • Van ’T Oever H.J.
        • Nijholt I.M.
        • et al.
        Systematic review of reproductive outcomes after High Intensity Focused Ultrasound treatment of uterine fibroids.
        Eur J Radiol. 2021; 141: 109801
        • Hesley G.K.
        • Gorny K.R.
        • Woodrum D.A.
        MR-Guided Focused Ultrasound for the Treatment of Uterine Fibroids.
        CardioVascular Interv Radiol. 2013; 36: 5-13
        • Mindjuk I.
        • Trumm C.G.
        • Herzog P.
        • et al.
        MRI predictors of clinical success in MR-guided focused ultrasound (MRgFUS) treatments of uterine fibroids: results from a single centre.
        Eur Radiol. 2015; 25: 1317-1328
        • Duc N.M.
        • Keserci B.
        Review of influential clinical factors in reducing the risk of unsuccessful MRI-guided HIFU treatment outcome of uterine fibroids.
        Diagn Interv Radiol. 2018; 24: 283-291
        • Lee B.B.
        • Yu S.P.
        Radiofrequency Ablation of Uterine Fibroids: a Review.
        Curr Obstet Gynecol Rep. 2016; 5: 318-324
        • Bradley L.D.
        • Pasic R.P.
        • Miller L.E.
        Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies.
        J Laparoendoscopic Adv Surg Tech. 2019; 29: 1507-1517
        • Taheri M.
        • Galo L.
        • Potts C.
        • et al.
        Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions.
        Int J Hyperthermia. 2019; 36: 295-301
        • Garza Leal J.G.
        • Hernandez Leon I.
        • Castillo Saenz L.
        • et al.
        Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System.
        J Minim Invasive Gynecol. 2011; 18: 364-371
        • Berman J.M.
        • Guido R.S.
        • Garza Leal J.G.
        • et al.
        Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas.
        J Minim Invasive Gynecol. 2014; 21: 767-774
        • Hahn M.
        • Brucker S.
        • Kraemer D.
        • et al.
        Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial.
        Geburtshilfe und Frauenheilkunde. 2015; 75: 442-449
        • Rattray D.D.
        • Weins L.
        • Regush L.C.
        • et al.
        Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada.
        Clinicoecon Outcomes Res. 2018; 10: 201-212
        • Aarts J.W.
        • Nieboer T.E.
        • Johnson N.
        • et al.
        Surgical approach to hysterectomy for benign gynaecological disease.
        Cochrane Database Syst Rev. 2015; 8: CD003677
        • Brölmann H.
        • Bongers M.
        • Garza-Leal J.G.
        • et al.
        The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids.
        Gynecol Surg. 2016; 13: 27-35
        • Brooks E.A.
        • Singer A.M.
        • Delvadia D.R.
        • et al.
        The CHOICES Study: Facility Level Comparative Cost, Resource Utilization, and Outcomes Analysis of Myomectomy Compared to Transcervical Fibroid Ablation.
        Clinicoecon Outcomes Res. 2020; 12: 299-306
        • Chudnoff S.
        • Guido R.
        • Roy K.
        • et al.
        Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas.
        Obstet Gynecol. 2019; 133: 13-22
        • Lukes A.
        • Green M.A.
        Three-Year Results of the SONATA Pivotal Trial of Transcervical Fibroid Ablation for Symptomatic Uterine Myomata.
        J Gynecol Surg. 2020; 36: 228-233
        • Garza-Leal J.G.
        Long-Term Clinical Outcomes of Transcervical Radiofrequency Ablation of Uterine Fibroids: The VITALITY Study.
        J Gynecol Surg. 2019; 35: 19-23
        • Miller C.E.
        • Osman K.M.
        Transcervical Radiofrequency Ablation of Symptomatic Uterine Fibroids: 2-Year Results of the SONATA Pivotal Trial.
        J Gynecol Surg. 2019; 35: 345-349
        • Shifrin G.
        • Engelhardt M.
        • Gee P.
        • et al.
        Transcervical fibroid ablation with the Sonata™ system for treatment of submucous and large uterine fibroids.
        Int J Gynaecol Obstet. 2021; 155: 79-85
        • Parker W.H.
        • Einarsson J.
        • Istre O.
        • et al.
        Risk factors for uterine rupture after laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2010; 17: 551-554
        • Sizzi O.
        • Rossetti A.
        • Malzoni M.
        • et al.
        Italian multicenter study on complications of laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2007; 14: 453-462
        • Bongers M.
        • Gupta J.
        • Garza-Leal J.G.
        • et al.
        The INTEGRITY Trial: Preservation of Uterine-Wall Integrity 12 Months After Transcervical Fibroid Ablation with the Sonata System.
        J Gynecol Surg. 2019; 35: 299-303
        • Bongers M.
        • Quinn S.D.
        • Mueller M.D.
        • et al.
        Evaluation of uterine patency following transcervical uterine fibroid ablation with the Sonata system (the OPEN clinical trial).
        Eur J Obstet Gynecol Reprod Biol. 2019; 242: 122-125
        • Keltz J.
        • Levie M.
        • Chudnoff S.
        Pregnancy Outcomes After Direct Uterine Myoma Thermal Ablation: Review of the Literature.
        J Minim Invasive Gynecol. 2017; 24: 538-545
        • Khaw S.C.
        • Anderson R.A.
        • Lui M.W.
        Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids.
        Reprod Biomed Online. 2020; 40: 429-444
        • Polin M.
        • Hur H.-C.
        Radiofrequency ablation of uterine fibroids and pregnancy outcomes: an updated review of the literature.
        J Minimally Invasive Gynecol. 2022;